Cagrilintide
MODERATE EVIDENCEAlso known as: AM833
Investigational — in clinical trials, not approved
Educational Overview
A long-acting amylin analogue under clinical investigation for metabolic and appetite-regulation research, studied both alone and alongside GLP-1 receptor agonists.
Research Mechanism
Amylin receptor agonism is studied for effects on satiety signalling and gastric emptying. Trial data exists but the compound has not completed regulatory approval.
Areas of Study
- Appetite regulation (clinical trials)
- Combination metabolic research
Safety Considerations
Investigational. Not approved by the FDA for any indication. Human use outside a supervised clinical trial is not supported. Research material only.
Frequently Asked Questions
Is this approved for human use?
No. This material is supplied for laboratory research use only by qualified businesses and institutions. It is not a medicine and is not for human or veterinary consumption.
Do you provide purity documentation?
Certificates of analysis are available to approved accounts. Contact our team for batch-specific documentation.
References
References pending editorial review
We publish citations only after a qualified reviewer has verified them against the primary literature. We do not list references we have not checked. (1 queued.)
Last reviewed: 2026-07-23 · Status: in_review · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.